**Baseline electrocardiograph (ECG):**

Cardiac Monitoring

- Baseline electrocardiograph is required for all who
- Echo date: __ __ / __ __ / 20 __
- Time: __ __ : __ __
- QTc = ___ ___ ___
- QTc> 500 is associated with increased risk of life
- QTc is prolonged if > 440ms in men or > 460ms in women.

**Blood tests**

- Baseline echocardiogram is required for all who
- WCC <3.0 x 10^9/L and/or NC <1.5 x 10^9/L
- WCC 3.0-3.5 x 10^9/L and/or NC 1.5-2.0 x 10^9/L
- Fasting lipids, glucose, liver function test, troponin, CRP,

**Physical observations**

- Record participant’s weight, height, BMI, waist measurement
- and blood pressure (BP) on the weekly monitoring section of
- this form as baseline observations.

**Cardiac Monitoring**

- ECG is preferred or 0.440mm in men or >0.460mm in women.
- QTc> 450 (males), <470 (females)
- and associated with increased risk of the
- cardiac arrhythmias (bradycardia or tachycardia)

**Other abnormalities:**

- Date taken: ___ ___ / ___ ___ / 20 ___ ___

- Chest x-ray: YES / NO

**Recommended titration regimen**

From day 14 dose can be increased in 50mg intervals every 2 to 3 days depending on efficacy and side effects.

Maximum dose is 150mg. Clozapine levels should be assessed at per commencement protocol, or 5-side effects are apparent. There is evidence of infection, there are changes in medication that interact with clozapine, or changes in the use of drugs, smoking or caffeine (see JAMC Clinical Guidelines).

**Baseline electrocardiograph (ECG):**

- Baseline echocardiogram is required for all who
- Echo date: __ __ / __ __ / 20 __
- Time: __ __ : __ __
- QTc = ___ ___ ___
- QTc> 500 is associated with increased risk of life
- QTc is prolonged if > 440ms in men or > 460ms in women.

**Blood tests**

- Baseline echocardiogram is required for all who
- WCC <3.0 x 10^9/L and/or NC <1.5 x 10^9/L
- WCC 3.0-3.5 x 10^9/L and/or NC 1.5-2.0 x 10^9/L
- Fasting lipids, glucose, liver function test, troponin, CRP,

**Physical observations**

- Record participant’s weight, height, BMI, waist measurement
- and blood pressure (BP) on the weekly monitoring section of
- this form as baseline observations.

**Cardiac Monitoring**

- ECG is preferred or 0.440mm in men or >0.460mm in women.
- QTc> 450 (males), <470 (females)
- and associated with increased risk of the
- cardiac arrhythmias (bradycardia or tachycardia)

**Other abnormalities:**

- Date taken: ___ ___ / ___ ___ / 20 ___ ___

- Chest x-ray: YES / NO

**Recommended titration regimen**

From day 14 dose can be increased in 50mg intervals every 2 to 3 days depending on efficacy and side effects. Maximum dose is 150mg. Clozapine levels should be assessed at per commencement protocol, or if 5-side effects are apparent. There is evidence of infection, there are changes in medication that interact with clozapine, or changes in the use of drugs, smoking or caffeine (see JAMC Clinical Guidelines).
CLINICAL REMINDERS

<table>
<thead>
<tr>
<th>DETAILS OF PERSON FILLING IN THIS COLUMN</th>
</tr>
</thead>
</table>

**MR75D is not used**

**Waist measurement (cm)**

**Blood pressure**

**BMI (weight/height2)**

**Blood glucose level**

**Blood pressure**

**Temperature (°C)**

**Respiratory Rate**

**ECG**

**Troponin > 2 ULN and CRP elevated Urgent transfer to Emergency department. Urgent cardiology consultation – query myocarditis.**

**Troponin 1 to ≤ 2 ULN and elevated CRP Urgent cardiology consultation. Daily assess troponin, CRP and symptoms until features normalise.**

**Troponin > 2 ULN and normal CRP Urgent transfer to Emergency department. Urgent cardiology consultation – query ACS.**

**Weekly (days 7, 14, 21 and 28) Troponin T or I, CRP, Pulse, Blood Pressure, Respiratory rate.**

**Cardiac Monitoring Guidelines**

**Highly Specialised Drugs Program**

**SA Health**

**MR74D**